Lp(a): The Cholesterol Number Your Standard Panel Completely Misses

What is Lp(a)?

Lipoprotein(a) — Lp(a) — is an LDL-like particle with an extra protein attached: apolipoprotein(a), covalently bonded to the apolipoprotein B-100 (ApoB) core. This structural difference is not cosmetic. The apolipoprotein(a) component is structurally similar to plasminogen, the precursor to the enzyme that breaks down blood clots. That homology is why Lp(a) may promote both atherosclerosis (plaque buildup in artery walls) and thrombosis (clot formation) — and why it has been called "LDL with a clotting problem."

Lp(a) levels are 90% genetically determined at birth. Unlike LDL cholesterol, which responds significantly to diet, exercise, and statins, Lp(a) does not meaningfully change with lifestyle interventions. A person with a high Lp(a) has almost certainly always had a high Lp(a). You cannot exercise it down.

This genetic stability has a practical implication: unlike ApoB or LDL cholesterol, which merit repeated measurement to track changes, Lp(a) needs to be measured only once in a lifetime — ideally in early adulthood. If your level is below the risk threshold, it will likely stay there.

Why Your Standard Lipid Panel Doesn't Catch It

A standard lipid panel measures total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides. None of these numbers tells you anything about your Lp(a) level — because Lp(a) is not separated out by standard lab chemistry.

Lp(a) is typically measured using an immunoassay that specifically detects the apolipoprotein(a) component. This test is not included in routine cardiovascular risk panels, and many primary care physicians do not order it routinely — though that is changing fast.

The 2026 ACC/AHA Dyslipidemia Guideline, released March 13, 2026, marks the first time in a major US guideline that Lp(a) testing has been given a specific recommendation: measure Lp(a) once in all adults, as a one-time assessment of a genetically determined cardiovascular risk factor.

Before this guideline, the ESC/EAS (European Society of Cardiology / European Atherosclerosis Society) had already called for universal Lp(a) measurement in their 2023 Consensus Statement — calling it "a causal risk factor for ASCVD that is largely unmodified by lifestyle or most pharmacological interventions." The NLA (National Lipid Association) has also recommended targeted testing in high-risk individuals since 2019.

The Genetics: Why Race-Based Thresholds Are a Problem

Lp(a) levels vary substantially by ancestry — people of African ancestry have, on average, higher Lp(a) levels than people of European or Asian ancestry, and people of South Asian descent also tend toward higher levels. This variation has historically created confusion about what constitutes "high" Lp(a), because most reference ranges were derived from European-descent populations.

The honest answer: Lp(a) thresholds should ideally be calibrated to your ancestry. That said, the 2026 ACC/AHA guideline and most expert consensus panels use ≥125 nmol/L as the general threshold for elevated risk — roughly equivalent to ~50 mg/dL using the older mg/dL units — recognizing that this may under-identify risk in populations with higher baseline levels.

Genetic studies (Mendelian randomization) have shown that lifelong exposure to elevated Lp(a) — even at moderate elevations — is associated with meaningfully increased risk of heart attack and stroke. A landmark 2022 analysis in JAMA estimated that people with Lp(a) ≥125 nmol/L face approximately 1.4× the long-term risk of a first cardiovascular event compared to those below that threshold. At ≥250 nmol/L (roughly double), the risk climbs to approximately 2× or higher.

What the 2026 ACC/AHA Guidelines Say About Lp(a)

The updated American College of Cardiology / American Heart Association Dyslipidemia Guideline, published March 13, 2026, makes the following points about Lp(a) testing:

1. One-time testing is recommended for all adults — not just those with a family history of premature cardiovascular disease. The rationale: Lp(a) is a potent, independent risk factor that modifies the overall risk calculation and may affect treatment intensity.
2. Elevated Lp(a) ≥125 nmol/L is recognized as a risk-enhancing factor — similar to a family history of premature ASCVD, coronary artery calcium score >100 Agatston units, or premature menopause. Risk-enhancing factors can justify starting or intensifying lipid-lowering therapy earlier.
3. Statins do not meaningfully lower Lp(a) — though some newer therapies (PCSK9 inhibitors, pelacarsen, olpasiran) show promise. This means a person with very high Lp(a) and seemingly acceptable LDL-C may still have substantial residual risk that their standard lipid panel does not capture.
4. Lp(a) does not require fasting — it can be measured in a non-fasting sample and is not significantly affected by triglycerides, making it a practical addition to any routine blood draw.

Citation: American College of Cardiology/American Heart Association. "ACC/AHA Issue Updated Guideline for Managing Lipids, Cholesterol." News release. March 13, 2026. Available at: newsroom.heart.org

Reading Your Lp(a) Result

Lp(a) is reported in two common units:

• nmol/L (preferred): Measures the particle concentration directly
• mg/dL (older): Based on the mass of the Lp(a) particle

Note: The two units are not interchangeable via a simple conversion formula because Lp(a) particle size varies between individuals — a person's Lp(a) level in mg/dL will depend partly on the size of their particles.

Reference ranges and interpretation:

Reference ranges vary by lab. Quest Diagnostics, LabCorp, and most major labs now use nmol/L as their primary unit. Always check your specific lab's reference range — and if your result is near a decision threshold, discuss with your provider before drawing strong conclusions.

What You Can Actually Do About High Lp(a)

Here is the uncomfortable truth: most therapies that lower LDL-C do not significantly lower Lp(a).

Statins (atorvastatin, rosuvastatin, etc.) lower LDL-C effectively but have little to no effect on Lp(a) levels. This is clinically important: a patient who achieves an excellent LDL-C on a high-intensity statin may still carry very high Lp(a) and therefore have meaningful residual cardiovascular risk that their LDL-C number does not reflect.

What does lower Lp(a)?

• PCSK9 inhibitors (evolocumab, alirocumab): Lower Lp(a) by approximately 20–30% as a byproduct of their LDL-lowering mechanism. Not currently indicated specifically for Lp(a), but patients with very high Lp(a) who also need aggressive LDL-C lowering may benefit.
• Pelacarsen (IONIS-APO(a)-LRx): An antisense oligonucleotide specifically targeting apolipoprotein(a) production. Phase 3 HORIZON trial (2022) showed significant Lp(a) reductions of 80%+ at higher doses. FDA review ongoing as of 2024–2025.
• Olpasiran: A siRNA therapy targeting LPA gene (which encodes apolipoprotein[a]). Phase 2 data showed 90%+ reductions in Lp(a). Phase 3 trials ongoing.
• Aspirin (low-dose): Does not lower Lp(a) but may reduce the thrombotic risk that high Lp(a) confers. The 2026 ACC/AHA guideline addresses aspirin use for primary prevention in patients with elevated Lp(a) as part of individualized decision-making.
• Niacin: Lowers Lp(a) modestly but is rarely used due to side effects and lack of outcome benefit in major trials (AIM-HIGH, HPS2-THRIVE).

What still matters even with high Lp(a):

• Aggressive LDL-C lowering (still reduces the remaining ASCVD risk)
• Blood pressure control
• Smoking cessation
• Weight management
• Tight glycemic control in diabetes

High Lp(a) amplifies existing risk — it does not eliminate the benefit of controlling other modifiable factors. A person with elevated Lp(a) who also has controlled LDL-C, blood pressure, and blood sugar is in a meaningfully better position than one who does not.

If you have elevated Lp(a) and a family history of early cardiovascular disease, a lipid specialist or preventive cardiologist may be the right clinician to help you manage the full picture.

Labwise does not sell tests. We explain them.

Frequently Asked Questions

How is Lp(a) different from LDL cholesterol?
LDL cholesterol is a measure of the cholesterol content inside LDL particles. Lp(a) is a genetically distinct particle — an LDL core plus an apolipoprotein(a) tail — that carries cholesterol but also has pro-thrombotic properties. Think of Lp(a) as LDL with a second risk mechanism built in. Standard LDL-C tests do not distinguish Lp(a) from other LDL particles; you need a separate Lp(a) test to know your level.

Do I need to fast for an Lp(a) test?
No. Lp(a) is not significantly affected by fasting, and it does not track with triglycerides the way some other lipoprotein measurements do. You can get an Lp(a) test on a non-fasting blood draw.

How much does an Lp(a) test cost?
Out of pocket at major labs: approximately $40–$75 at Quest or LabCorp. Insurance coverage varies — with an appropriate diagnosis code (elevated cardiovascular risk, family history of premature ASCVD, or the new 2026 ACC/AHA recommendation for universal one-time measurement), many plans cover it. Direct-to-consumer platforms like InsideTracker and HealthLabs also offer Lp(a) testing without a doctor's order.

Does exercise or diet lower Lp(a)?
No meaningful effect has been demonstrated. Unlike LDL-C, which responds to dietary changes, weight loss, and exercise, Lp(a) is largely set by genetics and is not modifiable through lifestyle. This is why the 2026 ACC/AHA guideline frames Lp(a) measurement as a one-time assessment — your level does not change enough over time to warrant repeat testing.

Should I take aspirin if I have high Lp(a)?
The decision to use aspirin for primary cardiovascular prevention is individual and depends on your age, bleeding risk, overall risk profile, and other factors. High Lp(a) may tilt the benefit/risk calculation toward aspirin in some cases — but do not start without discussing it with your provider. The 2026 ACC/AHA guideline addresses aspirin use in patients with risk-enhancing factors including elevated Lp(a) in the context of shared decision-making.

My LDL is fine — do I still need to worry about Lp(a)?
Possibly yes. Lp(a) is an independent risk factor — meaning it adds cardiovascular risk on top of what your LDL-C already explains. A person with normal LDL-C but very high Lp(a) may have a similar or even higher cardiovascular risk than a person with elevated LDL-C and normal Lp(a). The 2026 ACC/AHA guideline specifically identifies elevated Lp(a) as a risk-enhancing factor that can justify earlier or more aggressive lipid-lowering therapy.

My family history is clear — should I still get tested?
Yes, per the 2026 ACC/AHA guideline. The recommendation is universal one-time measurement in adulthood. Even people with no family history of early cardiovascular disease benefit from knowing their Lp(a) level because it is a lifelong, largely unmodifiable risk factor — and knowledge matters for long-term risk management.